Physiological Disposition of Hmg-Coa-Reductase Inhibitors
- 1 January 1990
- journal article
- review article
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 22 (4), 333-362
- https://doi.org/10.3109/03602539009041088
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivoBiochemical and Biophysical Research Communications, 1989
- Discovery, biochemistry and biology of lovastatinThe American Journal of Cardiology, 1988
- Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitorsKlinische Wochenschrift, 1988
- New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.Circulation, 1987
- Cytochrome P-450—Catalyzed Formation of Δ 4 -VPA, a Toxic Metabolite of Valproic AcidScience, 1987
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal speciesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- Drugs inhibiting HMG-CoA reductasePharmacology & Therapeutics, 1985
- Oxidation of monosubstituted olefins by cytochromes P-450 and heme models: Evidence for the formation of aldehydes in addition to epoxides and allylic alcoholsBiochemical and Biophysical Research Communications, 1984
- Microbial hydroxylation of ML-236B (compactin) and monacolin K (MB-530B)The Journal of Antibiotics, 1983